ClinicalTrials.gg
CompletedNCT02822794Updated Nov 14, 2018Results posted

Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen

A Phase 3 interventional study of SOF/VEL and RBV in Hepatitis C Virus Infection, sponsored by Gilead Sciences. Completed at 18 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-11-14.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
117
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 94 studies testing sofosbuvir in Hepatitis C — 1 open to participants now, 3 under way, none of them phase 3. Sofosbuvir · Hepatitis C.

Enrollment
33rd of 94
117 · median 75
Started
2016
with 12 others
Phase 3
30 of 94
none open now
Registered
55th of 94
by date
Lead sponsor
30 of 94
Gilead Sciences

Among the 94 studies testing sofosbuvir in Hepatitis C, this one is the 33rd largest by enrollment, is one of 13 that started in 2016, is one of 30 in phase 3, and was the 55th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

1 of the 94 studies testing sofosbuvir in Hepatitis C is open now. Recruiting first, the newest first:

About sofosbuvir

Sofosbuvir: first FDA approval 2013 (SOVALDI), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing sofosbuvir in Hepatitis C, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the antiviral efficacy, safety, and tolerability of therapy with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) and ribavirin (RBV) in participants with chronic genotype 1 or 2 hepatitis C virus (HCV) infection who have previously failed a direct-acting antiviral (DAA)-containing regimen.

03

Conditions studied

  • Hepatitis C Virus Infection

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Genotype 1 or 2 infection
  • Chronic HCV infection (≥ 6 months prior to screening) documented by prior medical history or liver
  • Previously treated with a DAA-containing regimen of at least 4 week duration

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
117 participants (actual)

Study arms

  • Experimental
    SOF/VEL FDC + RBV 12 weeks

    SOF/VEL FDC + RBV for 12 weeks in participants with genotype 1 or 2 HCV infection

    Drug: SOF/VEL · Drug: RBV

  • Experimental
    SOF/VEL FDC + RBV 24 weeks

    SOF/VEL FDC + RBV for 24 weeks in participants with genotype 1 or 2 HCV infection

    Drug: SOF/VEL · Drug: RBV

Interventions

  • DrugSOF/VEL

    Drug pages: Sofosbuvir · Velpatasvir

    400/100 mg tablet administered orally once daily

    Also known as: GS-7977/GS-5816, Epclusa®

  • DrugRBV

    Capsules administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, \> 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)

    Also known as: REBETOL®

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)

    SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.

    Time frame: Posttreatment Week 12

  2. Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)

    SVR4 was defined as HCV RNA \< LLOQ at 4 weeks after stopping study treatment.

    Time frame: Posttreatment Week 4

  2. Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)

    SVR 24 was defined as HCV RNA \< LLOQ at 24 weeks after stopping study treatment.

    Time frame: Posttreatment Week 24

  3. Percentage of Participants With HCV RNA < LLOQ at Week 1

    Time frame: Week 1

  4. Percentage of Participants With HCV RNA < LLOQ at Week 2

    Time frame: Week 2

  5. Percentage of Participants With HCV RNA < LLOQ at Week 3

    Time frame: Week 3

  6. Percentage of Participants With HCV RNA < LLOQ at Week 4

    Time frame: Week 4

  7. Percentage of Participants With HCV RNA < LLOQ at Week 5

    Time frame: Week 5

  8. Percentage of Participants With HCV RNA < LLOQ at Week 6

    Time frame: Week 6

  9. Percentage of Participants With HCV RNA < LLOQ at Week 8

    Time frame: Week 8

  10. Percentage of Participants With HCV RNA < LLOQ at Week 10

    Time frame: Week 10

  11. Percentage of Participants With HCV RNA < LLOQ at Week 12

    Time frame: Week 12

  12. Percentage of Participants With HCV RNA < LLOQ at Week 16

    Time frame: Week 16

  13. Percentage of Participants With HCV RNA < LLOQ at Week 20

    Time frame: Week 20

  14. Percentage of Participants With HCV RNA < LLOQ at Week 24

    Time frame: Week 24

  15. Change From Baseline in HCV RNA at Week 1

    Time frame: Baseline; Week 1

  16. Change From Baseline in HCV RNA at Week 2

    Time frame: Baseline; Week 2

  17. Change From Baseline in HCV RNA at Week 3

    Time frame: Baseline; Week 3

  18. Change From Baseline in HCV RNA at Week 4

    Time frame: Baseline; Week 4

  19. Change From Baseline in HCV RNA at Week 5

    Time frame: Baseline; Week 5

  20. Change From Baseline in HCV RNA at Week 6

    Time frame: Baseline; Week 6

  21. Change From Baseline in HCV RNA at Week 8

    Time frame: Baseline; Week 8

  22. Change From Baseline in HCV RNA at Week 10

    Time frame: Baseline; Week 10

  23. Change From Baseline in HCV RNA at Week 12

    Time frame: Baseline; Week 12

  24. Change From Baseline in HCV RNA at Week 16

    Time frame: Baseline; Week 16

  25. Change From Baseline in HCV RNA at Week 20

    Time frame: Baseline; Week 20

  26. Change From Baseline in HCV RNA at Week 24

    Time frame: Baseline; Week 24

  27. Percentage of Participants With Overall Virologic Failure

    Virologic failure was defined as: * On-treatment virologic failure: * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment), or * Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment) * Virologic relapse: * Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at last on-treatment visit.

    Time frame: Up to Posttreatment Week 24

07

Results

Posted Jul 3, 2018

Participant flow

Participants were enrolled at study sites in Japan. The first participant was screened on 25 July 2016. The last study visit occurred on 25 August 2017.

Participant flow — Overall Study
MilestoneSOF/VEL FDC + RBV 12 WeeksSOF/VEL FDC + RBV 24 Weeks
Started5760
Completed5660
Not completed10
Withdrew: Withdrew consent10

Outcome measures

PrimaryPercentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)

SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.

Time frame:
Posttreatment Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
percentage of participantsSOF/VEL+RBV 12 Weeks (GT1)SOF/VEL+RBV 12 Weeks (GT2)SOF/VEL+RBV 24 Weeks (GT1)SOF/VEL+RBV 24 Weeks (GT2)
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)85.1 (71.7 to 93.8)70.0 (34.8 to 93.3)97.9 (88.9 to 99.9)91.7 (61.5 to 99.8)
Statistical analysis
  • SOF/VEL+RBV 12 Weeks (GT1) · Binomial test · p = <0.001P-value is obtained from the 2-sided exact 1-sample binomial test for the superiority of SOF/VEL+RBV 12 Weeks (GT1) over the performance goal of 50%.
  • SOF/VEL+RBV 24 Weeks (GT1) · Binomial test · p = <0.001P-value is obtained from the 2-sided exact 1-sample binomial test for the superiority of SOF/VEL +RBV 24 Weeks (GT1) over the performance goal of 50%.
PrimaryPercentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
Time frame:
Up to 24 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
percentage of participantsSOF/VEL+RBV 12 WeeksSOF/VEL+RBV 24 Weeks
Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event1.83.3
SecondaryPercentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)

SVR4 was defined as HCV RNA \< LLOQ at 4 weeks after stopping study treatment.

Time frame:
Posttreatment Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)
percentage of participantsSOF/VEL+RBV 12 WeeksSOF/VEL+RBV 24 Weeks
Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)86.0 (74.2 to 93.7)98.3 (91.1 to 100.0)
SecondaryPercentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)

SVR 24 was defined as HCV RNA \< LLOQ at 24 weeks after stopping study treatment.

Time frame:
Posttreatment Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)
percentage of participantsSOF/VEL+RBV 12 WeeksSOF/VEL+RBV 24 Weeks
Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)82.5 (70.1 to 91.3)96.7 (88.5 to 99.6)
SecondaryPercentage of Participants With HCV RNA < LLOQ at Week 1
Time frame:
Week 1
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA < LLOQ at Week 1
percentage of participantsSOF/VEL+RBV 12 WeeksSOF/VEL+RBV 24 Weeks
Percentage of Participants With HCV RNA < LLOQ at Week 121.1 (11.4 to 33.9)25.0 (14.7 to 37.9)
SecondaryPercentage of Participants With HCV RNA < LLOQ at Week 2
Time frame:
Week 2
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA < LLOQ at Week 2
percentage of participantsSOF/VEL+RBV 12 WeeksSOF/VEL+RBV 24 Weeks
Percentage of Participants With HCV RNA < LLOQ at Week 264.3 (50.4 to 76.6)70.0 (56.8 to 81.2)
SecondaryPercentage of Participants With HCV RNA < LLOQ at Week 3
Time frame:
Week 3
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA < LLOQ at Week 3
percentage of participantsSOF/VEL+RBV 12 WeeksSOF/VEL+RBV 24 Weeks
Percentage of Participants With HCV RNA < LLOQ at Week 391.1 (80.4 to 97.0)90.0 (79.5 to 96.2)
SecondaryPercentage of Participants With HCV RNA < LLOQ at Week 4
Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA < LLOQ at Week 4
percentage of participantsSOF/VEL+RBV 12 WeeksSOF/VEL+RBV 24 Weeks
Percentage of Participants With HCV RNA < LLOQ at Week 498.2 (90.4 to 100.0)98.3 (91.1 to 100.0)
SecondaryPercentage of Participants With HCV RNA < LLOQ at Week 5
Time frame:
Week 5
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA < LLOQ at Week 5
percentage of participantsSOF/VEL+RBV 12 WeeksSOF/VEL+RBV 24 Weeks
Percentage of Participants With HCV RNA < LLOQ at Week 598.2 (90.4 to 100.0)98.3 (91.1 to 100.0)
SecondaryPercentage of Participants With HCV RNA < LLOQ at Week 6
Time frame:
Week 6
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA < LLOQ at Week 6
percentage of participantsSOF/VEL+RBV 12 WeeksSOF/VEL+RBV 24 Weeks
Percentage of Participants With HCV RNA < LLOQ at Week 6100.0 (93.6 to 100.0)98.3 (91.1 to 100.0)
SecondaryPercentage of Participants With HCV RNA < LLOQ at Week 8
Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA < LLOQ at Week 8
percentage of participantsSOF/VEL+RBV 12 WeeksSOF/VEL+RBV 24 Weeks
Percentage of Participants With HCV RNA < LLOQ at Week 8100.0 (93.6 to 100.0)100.0 (94.0 to 100.0)
SecondaryPercentage of Participants With HCV RNA < LLOQ at Week 10
Time frame:
Week 10
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA < LLOQ at Week 10
percentage of participantsSOF/VEL+RBV 12 WeeksSOF/VEL+RBV 24 Weeks
Percentage of Participants With HCV RNA < LLOQ at Week 10100.0 (93.6 to 100.0)100.0 (93.9 to 100.0)
SecondaryPercentage of Participants With HCV RNA < LLOQ at Week 12
Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA < LLOQ at Week 12
percentage of participantsSOF/VEL+RBV 12 WeeksSOF/VEL+RBV 24 Weeks
Percentage of Participants With HCV RNA < LLOQ at Week 12100.0 (93.6 to 100.0)100.0 (93.9 to 100.0)
SecondaryPercentage of Participants With HCV RNA < LLOQ at Week 16
Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA < LLOQ at Week 16
percentage of participantsSOF/VEL+RBV 24 Weeks
Percentage of Participants With HCV RNA < LLOQ at Week 16100.0 (93.8 to 100.0)
SecondaryPercentage of Participants With HCV RNA < LLOQ at Week 20
Time frame:
Week 20
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA < LLOQ at Week 20
percentage of participantsSOF/VEL+RBV 24 Weeks
Percentage of Participants With HCV RNA < LLOQ at Week 20100.0 (93.8 to 100.0)
SecondaryPercentage of Participants With HCV RNA < LLOQ at Week 24
Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA < LLOQ at Week 24
percentage of participantsSOF/VEL+RBV 24 Weeks
Percentage of Participants With HCV RNA < LLOQ at Week 24100.0 (93.8 to 100.0)
SecondaryChange From Baseline in HCV RNA at Week 1
Time frame:
Baseline; Week 1
Reported as:
Mean · log10 IU/mL
Change From Baseline in HCV RNA at Week 1
log10 IU/mLSOF/VEL+RBV 12 WeeksSOF/VEL+RBV 24 Weeks
Change From Baseline in HCV RNA at Week 1-4.40 ± 0.640-4.36 ± 0.698
SecondaryChange From Baseline in HCV RNA at Week 2
Time frame:
Baseline; Week 2
Reported as:
Mean · log10 IU/mL
Change From Baseline in HCV RNA at Week 2
log10 IU/mLSOF/VEL+RBV 12 WeeksSOF/VEL+RBV 24 Weeks
Change From Baseline in HCV RNA at Week 2-4.91 ± 0.510-4.89 ± 0.603
SecondaryChange From Baseline in HCV RNA at Week 3
Time frame:
Baseline; Week 3
Reported as:
Mean · log10 IU/mL
Change From Baseline in HCV RNA at Week 3
log10 IU/mLSOF/VEL+RBV 12 WeeksSOF/VEL+RBV 24 Weeks
Change From Baseline in HCV RNA at Week 3-5.07 ± 0.506-5.02 ± 0.575
SecondaryChange From Baseline in HCV RNA at Week 4
Time frame:
Baseline; Week 4
Reported as:
Mean · log10 IU/mL
Change From Baseline in HCV RNA at Week 4
log10 IU/mLSOF/VEL+RBV 12 WeeksSOF/VEL+RBV 24 Weeks
Change From Baseline in HCV RNA at Week 4-5.12 ± 0.486-5.04 ± 0.580
SecondaryChange From Baseline in HCV RNA at Week 5
Time frame:
Baseline; Week 5
Reported as:
Mean · log10 IU/mL
Change From Baseline in HCV RNA at Week 5
log10 IU/mLSOF/VEL+RBV 12 WeeksSOF/VEL+RBV 24 Weeks
Change From Baseline in HCV RNA at Week 5-5.13 ± 0.487-5.05 ± 0.579
SecondaryChange From Baseline in HCV RNA at Week 6
Time frame:
Baseline; Week 6
Reported as:
Mean · log10 IU/mL
Change From Baseline in HCV RNA at Week 6
log10 IU/mLSOF/VEL+RBV 12 WeeksSOF/VEL+RBV 24 Weeks
Change From Baseline in HCV RNA at Week 6-5.13 ± 0.492-5.05 ± 0.579
SecondaryChange From Baseline in HCV RNA at Week 8
Time frame:
Baseline; Week 8
Reported as:
Mean · log10 IU/mL
Change From Baseline in HCV RNA at Week 8
log10 IU/mLSOF/VEL+RBV 12 WeeksSOF/VEL+RBV 24 Weeks
Change From Baseline in HCV RNA at Week 8-5.13 ± 0.492-5.06 ± 0.584
SecondaryChange From Baseline in HCV RNA at Week 10
Time frame:
Baseline; Week 10
Reported as:
Mean · log10 IU/mL
Change From Baseline in HCV RNA at Week 10
log10 IU/mLSOF/VEL+RBV 12 WeeksSOF/VEL+RBV 24 Weeks
Change From Baseline in HCV RNA at Week 10-5.13 ± 0.492-5.06 ± 0.589
SecondaryChange From Baseline in HCV RNA at Week 12
Time frame:
Baseline; Week 12
Reported as:
Mean · log10 IU/mL
Change From Baseline in HCV RNA at Week 12
log10 IU/mLSOF/VEL+RBV 12 WeeksSOF/VEL+RBV 24 Weeks
Change From Baseline in HCV RNA at Week 12-5.13 ± 0.492-5.06 ± 0.589
SecondaryChange From Baseline in HCV RNA at Week 16
Time frame:
Baseline; Week 16
Reported as:
Mean · log10 IU/mL
Change From Baseline in HCV RNA at Week 16
log10 IU/mLSOF/VEL+RBV 24 Weeks
Change From Baseline in HCV RNA at Week 16-5.06 ± 0.594
SecondaryChange From Baseline in HCV RNA at Week 20
Time frame:
Baseline; Week 20
Reported as:
Mean · log10 IU/mL
Change From Baseline in HCV RNA at Week 20
log10 IU/mLSOF/VEL+RBV 24 Weeks
Change From Baseline in HCV RNA at Week 20-5.06 ± 0.594
SecondaryChange From Baseline in HCV RNA at Week 24
Time frame:
Baseline; Week 24
Reported as:
Mean · log10 IU/mL
Change From Baseline in HCV RNA at Week 24
log10 IU/mLSOF/VEL+RBV 24 Weeks
Change From Baseline in HCV RNA at Week 24-5.06 ± 0.594
SecondaryPercentage of Participants With Overall Virologic Failure

Virologic failure was defined as: * On-treatment virologic failure: * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment), or * Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment) * Virologic relapse: * Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at last on-treatment visit.

Time frame:
Up to Posttreatment Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Overall Virologic Failure
percentage of participantsSOF/VEL+RBV 12 WeeksSOF/VEL+RBV 24 Weeks
Percentage of Participants With Overall Virologic Failure15.83.3

Adverse events

Collected over Adverse Events and Serious Adverse Events: Up to 24 weeks + 30 days. All-Cause Mortality: Up to Posttreatment Week 24.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SOF/VEL+RBV 12 Weeks0/57 (0%)0/57 (0%)43/57 (75.4%)
SOF/VEL+RBV 24 Weeks0/60 (0%)4/60 (6.7%)38/60 (63.3%)
Most frequent serious events
Most frequent serious events
EventSOF/VEL+RBV 12 WeeksSOF/VEL+RBV 24 Weeks
Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/572/60
PneumoniaInfections and infestations0/571/60
Hepatic angiosarcomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/571/60
Most frequent other events
Showing 10 of 16
Most frequent other events
EventSOF/VEL+RBV 12 WeeksSOF/VEL+RBV 24 Weeks
Viral upper respiratory tract infectionInfections and infestations20/5713/60
AnaemiaBlood and lymphatic system disorders14/5713/60
HeadacheNervous system disorders11/572/60
NauseaGastrointestinal disorders5/571/60
StomatitisGastrointestinal disorders5/573/60
Back painMusculoskeletal and connective tissue disorders4/571/60
EczemaSkin and subcutaneous tissue disorders4/572/60
GastroenteritisInfections and infestations0/574/60
Dry skinSkin and subcutaneous tissue disorders0/574/60
PruritusSkin and subcutaneous tissue disorders2/574/60

Baseline characteristics

Safety Analysis Set: participants who received at least 1 dose of study drug

Age, Continuous
Age, Continuous(years)SOF/VEL+RBV 12 Weeks (GT1)SOF/VEL+RBV 12 Weeks (GT2)SOF/VEL+RBV 24 Weeks (GT1)SOF/VEL+RBV 24 Weeks (GT2)Total
Mean63 ± 9.759 ± 15.764 ± 10.161 ± 7.263 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)SOF/VEL+RBV 12 Weeks (GT1)SOF/VEL+RBV 12 Weeks (GT2)SOF/VEL+RBV 24 Weeks (GT1)SOF/VEL+RBV 24 Weeks (GT2)Total
Female29528567
Male18520750
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SOF/VEL+RBV 12 Weeks (GT1)SOF/VEL+RBV 12 Weeks (GT2)SOF/VEL+RBV 24 Weeks (GT1)SOF/VEL+RBV 24 Weeks (GT2)Total
Asian47104812117
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SOF/VEL+RBV 12 Weeks (GT1)SOF/VEL+RBV 12 Weeks (GT2)SOF/VEL+RBV 24 Weeks (GT1)SOF/VEL+RBV 24 Weeks (GT2)Total
Not Hispanic or Latino47104812117
HCV genotype
HCV genotype(Participants)SOF/VEL+RBV 12 Weeks (GT1)SOF/VEL+RBV 12 Weeks (GT2)SOF/VEL+RBV 24 Weeks (GT1)SOF/VEL+RBV 24 Weeks (GT2)Total
Genotype 1a20103
Genotype 1b45047092
Genotype 2a/2c03047
Genotype 2b02046
Genotype 2 (No Confirmed Subtype)05049
IL28b Status
IL28b Status(Participants)SOF/VEL+RBV 12 Weeks (GT1)SOF/VEL+RBV 12 Weeks (GT2)SOF/VEL+RBV 24 Weeks (GT1)SOF/VEL+RBV 24 Weeks (GT2)Total
CC15821650
CT28120655
TT417012
HCV RNA (log10 IU/mL)
HCV RNA (log10 IU/mL)(log10 IU/mL)SOF/VEL+RBV 12 Weeks (GT1)SOF/VEL+RBV 12 Weeks (GT2)SOF/VEL+RBV 24 Weeks (GT1)SOF/VEL+RBV 24 Weeks (GT2)Total
Mean6.2 ± .476.6 ± .466.2 ± .516.2 ± .866.2 ± .54
HCV RNA Category
HCV RNA Category(Participants)SOF/VEL+RBV 12 Weeks (GT1)SOF/VEL+RBV 12 Weeks (GT2)SOF/VEL+RBV 24 Weeks (GT1)SOF/VEL+RBV 24 Weeks (GT2)Total
< 800,000 IU/mL10110425
≥ 800,000 IU/mL37938892
08

Study locations

18 sites
  • Ehime, Japan
  • Hiroshima, Japan
  • Ichikawa-shi, Japan
  • Iruma-gun, Japan
  • Kashihara, Japan
  • Kurume-shi, Japan
  • Kyoto, Japan
  • Maebashi, Japan
  • Musashino-shi, Japan
  • Nagoya, Japan
  • Nishinomiya, Japan
  • Ogaki City, Japan
  • Okayama, Japan
  • Omura, Japan
  • Sapporo, Japan
  • Suita, Japan
  • Takamatsu-shi, Japan
  • Yamagata, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2016 to primary completion in Jun 2017, 10 months.

Results were first posted in Jul 2018, 1 year 1 month after primary completion.

Of 68 industry-sponsored phase 3 interventional studies under Hepatitis C, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 18. This study's 10 months is below that.

Counting every sponsor, half of 90 studies reached it within 14 months; a quarter within 10 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2016
First posted
Jul 4, 2016
StartActual
Jul 25, 2016
Primary completionActual
Jun 2, 2017
CompletionActual
Aug 25, 2017
Results first posted
Jul 3, 2018
Last update
Nov 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02822794
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jul 4, 2016
Start date
Jul 25, 2016
Primary completion
Jun 2, 2017
Completion
Aug 25, 2017
Results posted
Jul 3, 2018
Last update
Nov 14, 2018

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sofosbuvir · Velpatasvir · Ribavirin

Start the discussion